MaxCyte (MXCT) to Announce Earnings on Wednesday

MaxCyte (NASDAQ:MXCT) is expected to post its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect MaxCyte to post earnings of ($0.12) per share and revenue of $6.5060 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.06. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%. The company had revenue of $6.22 million for the quarter, compared to analysts’ expectations of $7.28 million. On average, analysts expect MaxCyte to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

MaxCyte Price Performance

MXCT stock opened at $1.11 on Wednesday. MaxCyte has a 1 year low of $0.64 and a 1 year high of $2.19. The firm has a 50-day moving average of $1.19 and a 200 day moving average of $0.98. The company has a market cap of $118.90 million, a P/E ratio of -3.00 and a beta of 1.48.

Analysts Set New Price Targets

MXCT has been the topic of a number of research analyst reports. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings upgraded MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.00.

Hedge Funds Weigh In On MaxCyte

A number of institutional investors and hedge funds have recently made changes to their positions in MXCT. Kennedy Capital Management LLC purchased a new position in shares of MaxCyte during the third quarter valued at approximately $3,330,000. AXA S.A. grew its stake in shares of MaxCyte by 123.2% in the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after buying an additional 1,215,481 shares during the last quarter. Millennium Management LLC grew its stake in shares of MaxCyte by 1,082.6% in the 4th quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock worth $2,004,000 after buying an additional 1,183,461 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in MaxCyte during the 4th quarter valued at approximately $1,594,000. Finally, UBS Group AG increased its position in MaxCyte by 186.3% during the 3rd quarter. UBS Group AG now owns 474,487 shares of the company’s stock valued at $750,000 after buying an additional 308,769 shares in the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.